Elucid Bioimaging

Based in the United States, Elucid Bioimaging is a startup founded in 2016. Its most recent tracked round is Series C+. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

Elucid Bioimaging is a medical technology company leveraging machine intelligence to improve the accuracy, experience, and cost-effectiveness of vascular diagnostic imaging. Its flagship product, PlaqueIQ, is the first FDA-cleared and CE-marked, histology-validated, non-invasive image analysis software for evaluating coronary CT angiograms to provide multi-dimensional visualization, structural measurements, and plaque composition to inform risk of heart attack or stroke and personalized treatmen